Chemistry Firms Still Second Fiddle in Biology-Chemistry Mergers
Executive Summary
With a scarcity of well-trained chemists and exponentially increasing numbers of genomics-generated targets contributing to an already bulging lead identification/optimization bottleneck, medicinal chemistry capabilities are at a premium. Nonetheless, when it comes to market valuations, biology companies still come out on top. And Celera's recent acquisition of Axys, along with Lexicon Genetics purchase of Coelacanth help prove the point.
You may also be interested in...
Inside Applera: Celera Genomics Becomes Applied Bio's Diagnostics Angel
Applera Corp.'s new $75 million high-throughput genotyping initiative to be equally funded by its three businesses, Celera Genomics Group, Applied Biosystems Group, and Celera Diagnostics (a joint venture of Celera Genomics and Applied Bio) has provided a context for the company to begin to reveal its diagnostics strategy. New information about the structure of the joint venture also sheds more light on the acceleration of Celera Genomics' business strategy as it moves toward a collaborator-oriented drug discovery company model.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
FDA Sunsets VCRP, Will Launch New Portal For Mandatory Cosmetics Registration Under MoCRA
FDA is closing down its 50-year-old Voluntary Cosmetic Registration Program as it prepares a new portal for facility registration and product/ingredient listing under the Modernization of Cosmetic Regulations Act. The Independent Beauty Association says the news marked an important step, but dismayed many stakeholders who hoped VCRP data would transfer to the new system or otherwise be preserved.